<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256658</url>
  </required_header>
  <id_info>
    <org_study_id>CCOA566B2401</org_study_id>
    <secondary_id>CCOA566B2401E1</secondary_id>
    <nct_id>NCT01256658</nct_id>
  </id_info>
  <brief_title>A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)</brief_title>
  <official_title>A Cluster Randomized, Single-centre, Controlled, Parallel,12-month Prospective Study and Additional 12-month Follow-up in Africa of Malaria Incidence in a Community Setting Following Systematic Treatment of P. Falciparum Asymptomatic Carriers With Artemether-lumefantrine (Coartem® / Coartem® Dispersible)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and
      treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on a
      number of clinical malaria cases in children less than 5 years of age and the improvement of
      hemoglobin levels in the overall population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (&lt;5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)</measure>
    <time_frame>Month 12 of period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000s) per person-year in infants and children (&lt;5 years) in post Community Screening Campaign (CSC) at month 12 was detected by Rapid Diagnostic Test (RDT) (using a blood sample from each participant) and later confirmed to have a parasite density ≥5000/uL by microscopy.
Number of SMRC5000: sum of all SMRC5000 for all infants and children (&lt;5 years) in post CSC.
Person-year observed: sum of duration (in days) for all infants and children (&lt;5 years) in post CSC present in study /365.25.
Number of SMRC5000 per person-year = number of SMRC5000/person-year observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hemoglobin Level (g/dL) in Asymptomatic Carriers &gt;6 Months of Age (Per Cluster)</measure>
    <time_frame>Day 1 and day 28 of period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Change in hemoglobin levels from day 1 to day 28 was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each asymptomatic carrier from Community Screening Campaign 1 (CSC1), &gt; 6 months of age, at day 1 and at day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microscopy-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4) (Per Cluster)</measure>
    <time_frame>Month 12 - period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Microscopy confirmed gametocyte carriers at Community Screening Campaign 4(CSC4) were assessed via microscopy at month 12 of period 1. Blood films were histologically treated and examined microscopically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microscopy Confirmed Asymptomatic Carriers of P. Falciparum at Community Screening Campaign 4 (CSC4) (Per Cluster)</measure>
    <time_frame>Month 12 - period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Microscopy confirmation of asymptomatic carriers of P. falciparum at Community Screening Campaign 4 (CSC4) was conducted at month 12. Blood films were histologically treated and examined microscopically. When it was ascertained that P. falciparum was present, a count of the asexual forms against leukocytes was made using a tally counter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1(CSC1)/Day 1 to Community Screening Campaign 4 (CSC4)/Day 1 (Per Cluster)</measure>
    <time_frame>Day 1 (CSC1/day 1) and month 12 (CSC4/day 1) - period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Comparison of hemoglobin level (g/dL) from Community Screening Campaign 1 (CSC1)/Day 1 to Community Screening Campaign 4 (CSC4)/Day 1 in infants and children (&gt;6 months and &lt;5 years) by study arm was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Post Community Screening Campaign (CSC)</measure>
    <time_frame>12 months - period 1</time_frame>
    <description>Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000s) per person-year in post Community Screening Campaign (CSC), by study arm (individual level data) was detected by Rapid Diagnostic Test (RDT) (using a blood sample from each participant) and later confirmed to have a parasite density ≥5000/uL by microscopy.
Number of SMRC5000: sum of all SMRC5000 for all subjects in post CSC. Person-year observed: sum of duration (in days) in post CSC for all subjects present in study /365.25.
Number of SMRC5000 per person-year = number of SMRC5000/person-year observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC)</measure>
    <time_frame>12 months - period 1</time_frame>
    <description>Total number of participants (all ages) with hospitalizations, severe malaria episodes or death after Community Screening Campaign (CSC) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants (Infants and Children (&gt; 6 Months and &lt; 5 Years)) With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC)</measure>
    <time_frame>12 months - period 1</time_frame>
    <description>Total number of participants (infants and children (&gt; 6 months and &lt; 5 years)) with hospitalizations, severe malaria episodes or death after Community Screening Campaign (CSC) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Microscopy-confirmed Asymptomatic Carriers From Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster)</measure>
    <time_frame>12 months - period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Mean number of asymptomatic carriers from Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) was measured by confirmed positive microscopy for P. falciparum asexual forms in participants with absence of clinical signs and symptoms of malaria.
Mean measured in this analysis is the mean percent indicting the mean of percentages of cluster frequencies under the study arm for that particular category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Microscopy-confirmed Gametocyte Carriers at Day 1 of Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster)</measure>
    <time_frame>12 months - period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Mean number of gametocyte carriers at Day 1 for Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) was measured using gametocyte assessments (prevalence and density) via microscopy.
Mean measured in this analysis is the mean percent indicating the mean of percentages of cluster frequencies under the study arm for that particular category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Microscopy and qRT-PCR-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4)</measure>
    <time_frame>Month 12 (CSC4/day 1) - period 1</time_frame>
    <description>Number of gametocyte carriers at Community Screening Campaign 4 (CSC4) was measured via microscopy and confirmed using Quantitative Reverse Transcription PCR (qRT-PCR) at day 1 of CSC4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1 (CSC1)/Day 1 to CSC1/Day 28 in Infants and Children (&gt;6 Months and &lt;5 Years) for Asymptomatic Carriers at CSC1</measure>
    <time_frame>Day 1 and day 28 - period 1</time_frame>
    <description>Change in hemoglobin level (g/dL) from Community Screening Campaign 1 (CSC1)/Day 1 to CSC1/Day 28 in infants and children (&gt;6 Months and &lt;5 Years) for asymptomatic carriers at CSC1 was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia Status Based on Community Screening Campaign 1 (CSC1)/Day 1 in Infants and Children (&gt;6 Months and &lt;5 Years)</measure>
    <time_frame>Day 1 (CSC1/day 1) - period 1</time_frame>
    <description>Anemia status based on Community Screening Campaign 1 (CSC1)/Day 1 in infants and children (&gt;6 months and &lt;5 years) was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia Status Based on Community Screening Campaign 4 (CSC4)/Day 1 in Infants and Children (&gt;6 Months and &lt;5 Years)</measure>
    <time_frame>Month 12 (CSC4/day 1) - period 1</time_frame>
    <description>Anemia status based on Community Screening Campaign 4 (CSC4/Day 1) in infants and children (&gt;6 months and &lt;5 years) was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level (g/dL) in Community Screening Campaign 1 (CSC1)/Day 1 and CSC4/Day 1 by Study Arm and Age Group (Per Cluster)</measure>
    <time_frame>Day 1 (CSC1/day 1) and month 12 (CSC4/day 1) - period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Hemoglobin levels at Community Screening Campaign 1 and 4 (CSC1 and CSC4) on day 1 per age group (5-9 years, 10-14 years, and ≥15 years) in the intervention versus the control arm was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of COA566-treated Microscopy-confirmed Asymptomatic Carriers at Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3) With Parasitological Cure Rate at Day 7</measure>
    <time_frame>Day 7 of CSC1, CSC2 and CSC3 - period 1</time_frame>
    <description>Percentage of participants with parasitological cure confirmed via microscopy at day 7 after treatment with COA566. This assessment was done on asymptomatic carriers from Community Screening Campaigns 1, 2 and 3 (CSC1, CSC2 and CSC3) from the intervention group only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Microscopy-confirmed Gametocyte Carriers Treated With COA566 for Asymptomatic Carriers</measure>
    <time_frame>Day 1, day 7 and day 28 - period 1</time_frame>
    <description>Percentage of microscopy-confirmed gametocyte asymptomatic carriers treated with COA566 for asymptomatic carriers in Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Community Screening Campaign 1 (CSC1) Infants and Children (&gt;6 Months and &lt;5 Years)- Individual Data</measure>
    <time_frame>Day 1 to Day 28- period 1</time_frame>
    <description>Individual data of number of asymptomatic carriers with increase in hemoglobin levels by at least 0.5 g/dL from Day 1 to Day 28 from Community Screening Campaign 1 (CSC1) infants and children (&gt;6 months and &lt;5 years). Hemoglobin levels were measured using the HemoCue® rapid test. This test was performed with a drop of blood collected from the fingertip at Day 1 and at Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in Infants and Children (&gt;6 Months and &lt;5 Years)- Cluster Data</measure>
    <time_frame>Day 1 to day 28 - period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Cluster data of number of asymptomatic carriers with increase in hemoglobin levels by at least 0.5 g/dL from Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in infants and children (&gt;6 months and &lt;5 years) was measured by Hemoglobin levels based on microscopy reading.
Mean and Standard Deviation (SD) percent were measured indicating the mean and SD of percentages of cluster frequencies under the study arm for that particular category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000) in Asymptomatic Carriers at Any Time of Diagnosis (Per Cluster)</measure>
    <time_frame>12 months - period 1</time_frame>
    <description>Data is presented &quot;per cluster&quot;. Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) in asymptomatic carriers by study arm from all inhabitants diagnosed at any time for asymptomatic carriers. Number of SMRC5000s is measured by Rapid diagnostic test (RDT) and later confirmed to have a parasite density ≥ 5000/uL by microscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Asymptomatic Carriers With Complicated and Uncomplicated Episodes Combined</measure>
    <time_frame>12 months - period 1</time_frame>
    <description>Number of asymptomatic carriers diagnosed with 1 Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000), 2 SMRC5000, 3 SMRC5000 and &gt;3 SMRC5000 (complicated and uncomplicated episodes combined). Number of SMRC5000s is measured by Rapid diagnostic test (RDT) and later confirmed to have a parasite density ≥ 5000/uL by microscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Subjects With Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL From Week 1 to Week 50</measure>
    <time_frame>Week 1 to Week 50</time_frame>
    <description>Cumulative number of asymptomatic carriers having Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) from Week 1 to Week 50, was measured from group of participants diagnosed as asymptomatic carriers at Community Screening Campaign (CSC1)/Day1. Number of participants affected before and after diagnosed with ≥1 symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) (complicated and uncomplicated episodes combined). Number of SMRC5000s was detected by Rapid Diagnostic Test (RDT) using a blood sample from each participant and later confirmed to have a parasite density &gt; or = 5000/uL by microscopy.
Week (1-2) indicates day1 to day14, week (3-4) indicates day 15 to day 28, week (5-6) indicates day 29 to day 42, etc. After first diagnosis of asymptomatic carriers at CSC1/Day1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14075</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COA566</intervention_name>
    <description>COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Artemether-lumefantrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Subjects who were diagnosed as Asymptomatic Carrier (AC) by Rapid Diagnostic Test
             (RDT).

          -  Subjects who were diagnosed with a Symptomatic malaria episode, RDT-confirmed (SMRC)

        Exclusion:

          -  Body weight &lt;5 kg.

          -  Hypersensitivity to artemether-lumefantrine or to any of the excipients of the tablets
             or dispersible tablets.

          -  Presence of severe malaria signs and symptoms

          -  First trimester of pregnancy.

          -  Family history of congenital prolongation of the QTc interval or sudden death or with
             any other clinical condition known to prolong the QTc interval such as history of
             symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe
             cardiac disease.

          -  Taking drugs that are known to influence cardiac function and to prolong QTc interval,
             such as class IA and III: neuroleptics, antidepressant agents, certain antibiotics
             including some agents of the following classes: macrolides, fluoroquinolones,
             imidazole and triazole antifungal agents, certain non-sedating antihistamines.

          -  Known disturbances of electrolyte balance, e.g. hypokalemia or hypomagnesemia.

          -  Taking drugs which may be metabolized by cytochrome enzyme CYP2D6
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burkina Faso</city>
        <zip>2208</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre National de Recherche et de Formation sur le Paludisme</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <reference>
    <citation>Ogutu B, Tiono AB, Makanga M, Premji Z, Gbadoé AD, Ubben D, Marrast AC, Gaye O. Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? Malar J. 2010 Jan 22;9:30. doi: 10.1186/1475-2875-9-30.</citation>
    <PMID>20096111</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <results_first_submitted>July 23, 2013</results_first_submitted>
  <results_first_submitted_qc>November 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P. falciparum</keyword>
  <keyword>malaria</keyword>
  <keyword>asymptomatic carriers</keyword>
  <keyword>bed-nets</keyword>
  <keyword>ITN-insecticide-treated net</keyword>
  <keyword>idiopathic trigeminal neuralgia</keyword>
  <keyword>RDT-Rapid diagnostic test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an 18 clusters randomized study (1 cluster = 1 village). 14,075 participants were recruited during Period 1 (treatment); of these, 12,226 participants continued onto Period 2 (1 year follow-up) to assess longer term impact of initial intervention on malaria episodes. Period 2 was stopped and all participants discontinued.</recruitment_details>
      <pre_assignment_details>During period 1 clusters were randomized 1:1 to either the control or the intervention arm (9 clusters per arm). In the intervention arm subjects were screened for asymptomatic carriage of P. falciparum status and treated with COA566. In both arms, subjects were treated for symptomatic malaria episodes. During period 2 there was no study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6817"/>
                <participants group_id="P2" count="7258"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5897"/>
                <participants group_id="P2" count="6510"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="920"/>
                <participants group_id="P2" count="748"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="837"/>
                <participants group_id="P2" count="661"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 - Follow up Only - No Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5854">43 participants who completed period 1 did not enroll to continue on period 2</participants>
                <participants group_id="P2" count="6372">138 participants who completed period 1 did not enroll to continue on period 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Lost to Follow up</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="5777">43 participants who completed period 1 did not enroll to continue on period 2</participants>
                <participants group_id="P2" count="6287">138 participants who completed period 1 did not enroll to continue on period 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5854"/>
                <participants group_id="P2" count="6372"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6817"/>
            <count group_id="B2" value="7258"/>
            <count group_id="B3" value="14075"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.02" spread="20.67"/>
                    <measurement group_id="B2" value="22.62" spread="20.31"/>
                    <measurement group_id="B3" value="22.82" spread="20.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3656"/>
                    <measurement group_id="B2" value="3816"/>
                    <measurement group_id="B3" value="7472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3161"/>
                    <measurement group_id="B2" value="3442"/>
                    <measurement group_id="B3" value="6603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (&lt;5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000s) per person-year in infants and children (&lt;5 years) in post Community Screening Campaign (CSC) at month 12 was detected by Rapid Diagnostic Test (RDT) (using a blood sample from each participant) and later confirmed to have a parasite density ≥5000/uL by microscopy.
Number of SMRC5000: sum of all SMRC5000 for all infants and children (&lt;5 years) in post CSC.
Person-year observed: sum of duration (in days) for all infants and children (&lt;5 years) in post CSC present in study /365.25.
Number of SMRC5000 per person-year = number of SMRC5000/person-year observed.</description>
        <time_frame>Month 12 of period 1</time_frame>
        <population>The number of units represents the number of clusters that include all randomized infants and children (&lt;5 years) for which CSCs 1, 2, and 3 were conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (&lt;5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000s) per person-year in infants and children (&lt;5 years) in post Community Screening Campaign (CSC) at month 12 was detected by Rapid Diagnostic Test (RDT) (using a blood sample from each participant) and later confirmed to have a parasite density ≥5000/uL by microscopy.
Number of SMRC5000: sum of all SMRC5000 for all infants and children (&lt;5 years) in post CSC.
Person-year observed: sum of duration (in days) for all infants and children (&lt;5 years) in post CSC present in study /365.25.
Number of SMRC5000 per person-year = number of SMRC5000/person-year observed.</description>
          <population>The number of units represents the number of clusters that include all randomized infants and children (&lt;5 years) for which CSCs 1, 2, and 3 were conducted, data was available, and census data were obtained as per protocol.</population>
          <units>SMRC5000 per person-year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1255"/>
                <count group_id="O2" value="1235"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.436"/>
                    <measurement group_id="O2" value="1.60" spread="0.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin Level (g/dL) in Asymptomatic Carriers &gt;6 Months of Age (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Change in hemoglobin levels from day 1 to day 28 was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each asymptomatic carrier from Community Screening Campaign 1 (CSC1), &gt; 6 months of age, at day 1 and at day 28.</description>
        <time_frame>Day 1 and day 28 of period 1</time_frame>
        <population>The number of units represents the number of clusters that include all randomized, &gt; 6 months of age participants for which CSC1 was conducted, data was available and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Level (g/dL) in Asymptomatic Carriers &gt;6 Months of Age (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Change in hemoglobin levels from day 1 to day 28 was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each asymptomatic carrier from Community Screening Campaign 1 (CSC1), &gt; 6 months of age, at day 1 and at day 28.</description>
          <population>The number of units represents the number of clusters that include all randomized, &gt; 6 months of age participants for which CSC1 was conducted, data was available and census data were obtained as per protocol.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3523"/>
                <count group_id="O2" value="3207"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n = 2387, 2116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.81" spread="0.329"/>
                    <measurement group_id="O2" value="12.06" spread="0.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n = 1136, 1091)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.33" spread="0.318"/>
                    <measurement group_id="O2" value="11.86" spread="0.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microscopy-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4) (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Microscopy confirmed gametocyte carriers at Community Screening Campaign 4(CSC4) were assessed via microscopy at month 12 of period 1. Blood films were histologically treated and examined microscopically.</description>
        <time_frame>Month 12 - period 1</time_frame>
        <population>The number of units represents the number of clusters that include all randomized participants for which CSC4 was conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Microscopy-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4) (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Microscopy confirmed gametocyte carriers at Community Screening Campaign 4(CSC4) were assessed via microscopy at month 12 of period 1. Blood films were histologically treated and examined microscopically.</description>
          <population>The number of units represents the number of clusters that include all randomized participants for which CSC4 was conducted, data was available, and census data were obtained as per protocol.</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.41"/>
                    <measurement group_id="O2" value="5.1" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microscopy Confirmed Asymptomatic Carriers of P. Falciparum at Community Screening Campaign 4 (CSC4) (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Microscopy confirmation of asymptomatic carriers of P. falciparum at Community Screening Campaign 4 (CSC4) was conducted at month 12. Blood films were histologically treated and examined microscopically. When it was ascertained that P. falciparum was present, a count of the asexual forms against leukocytes was made using a tally counter.</description>
        <time_frame>Month 12 - period 1</time_frame>
        <population>The number of units represents the number of clusters that include all randomized participants for which CSC4 was conducted, data was available, and census data was obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Microscopy Confirmed Asymptomatic Carriers of P. Falciparum at Community Screening Campaign 4 (CSC4) (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Microscopy confirmation of asymptomatic carriers of P. falciparum at Community Screening Campaign 4 (CSC4) was conducted at month 12. Blood films were histologically treated and examined microscopically. When it was ascertained that P. falciparum was present, a count of the asexual forms against leukocytes was made using a tally counter.</description>
          <population>The number of units represents the number of clusters that include all randomized participants for which CSC4 was conducted, data was available, and census data was obtained as per protocol.</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2023"/>
                <count group_id="O2" value="815"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="1.86"/>
                    <measurement group_id="O2" value="37.6" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1(CSC1)/Day 1 to Community Screening Campaign 4 (CSC4)/Day 1 (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Comparison of hemoglobin level (g/dL) from Community Screening Campaign 1 (CSC1)/Day 1 to Community Screening Campaign 4 (CSC4)/Day 1 in infants and children (&gt;6 months and &lt;5 years) by study arm was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant.</description>
        <time_frame>Day 1 (CSC1/day 1) and month 12 (CSC4/day 1) - period 1</time_frame>
        <population>The number of units represents the number of clusters that include all infants and children (&gt;6 months and &lt;5 years) randomized participants for which CSCs 1 and 4 were conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1(CSC1)/Day 1 to Community Screening Campaign 4 (CSC4)/Day 1 (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Comparison of hemoglobin level (g/dL) from Community Screening Campaign 1 (CSC1)/Day 1 to Community Screening Campaign 4 (CSC4)/Day 1 in infants and children (&gt;6 months and &lt;5 years) by study arm was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant.</description>
          <population>The number of units represents the number of clusters that include all infants and children (&gt;6 months and &lt;5 years) randomized participants for which CSCs 1 and 4 were conducted, data was available, and census data were obtained as per protocol.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1167"/>
                <count group_id="O2" value="1148"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC1/Day 1 (n= 819, 827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.24" spread="0.371"/>
                    <measurement group_id="O2" value="10.04" spread="0.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4/Day 1 (n= 348,321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.99" spread="0.267"/>
                    <measurement group_id="O2" value="11.13" spread="0.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Post Community Screening Campaign (CSC)</title>
        <description>Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000s) per person-year in post Community Screening Campaign (CSC), by study arm (individual level data) was detected by Rapid Diagnostic Test (RDT) (using a blood sample from each participant) and later confirmed to have a parasite density ≥5000/uL by microscopy.
Number of SMRC5000: sum of all SMRC5000 for all subjects in post CSC. Person-year observed: sum of duration (in days) in post CSC for all subjects present in study /365.25.
Number of SMRC5000 per person-year = number of SMRC5000/person-year observed.</description>
        <time_frame>12 months - period 1</time_frame>
        <population>Individual subject data from eligible clusters set defined as all randomized participants for which CSCs 1, 2, 3 and 4 were conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Post Community Screening Campaign (CSC)</title>
          <description>Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000s) per person-year in post Community Screening Campaign (CSC), by study arm (individual level data) was detected by Rapid Diagnostic Test (RDT) (using a blood sample from each participant) and later confirmed to have a parasite density ≥5000/uL by microscopy.
Number of SMRC5000: sum of all SMRC5000 for all subjects in post CSC. Person-year observed: sum of duration (in days) in post CSC for all subjects present in study /365.25.
Number of SMRC5000 per person-year = number of SMRC5000/person-year observed.</description>
          <population>Individual subject data from eligible clusters set defined as all randomized participants for which CSCs 1, 2, 3 and 4 were conducted, data was available, and census data were obtained as per protocol.</population>
          <units>SMRC5000 per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6817"/>
                <count group_id="O2" value="7258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45"/>
                    <measurement group_id="O2" value="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC)</title>
        <description>Total number of participants (all ages) with hospitalizations, severe malaria episodes or death after Community Screening Campaign (CSC) was assessed.</description>
        <time_frame>12 months - period 1</time_frame>
        <population>Safety analyzable asymptomatic carriers set consisted of all consenting inhabitants from intervention clusters confirmed positive by RDT for P. falciparum asexual forms at any CSC or when migrating into the cluster, in the absence of clinical signs and symptoms who received at least one dose of COA566 to treat the diagnosed asymptomatic infection.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC)</title>
          <description>Total number of participants (all ages) with hospitalizations, severe malaria episodes or death after Community Screening Campaign (CSC) was assessed.</description>
          <population>Safety analyzable asymptomatic carriers set consisted of all consenting inhabitants from intervention clusters confirmed positive by RDT for P. falciparum asexual forms at any CSC or when migrating into the cluster, in the absence of clinical signs and symptoms who received at least one dose of COA566 to treat the diagnosed asymptomatic infection.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6817"/>
                <count group_id="O2" value="7258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe malaria episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants (Infants and Children (&gt; 6 Months and &lt; 5 Years)) With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC)</title>
        <description>Total number of participants (infants and children (&gt; 6 months and &lt; 5 years)) with hospitalizations, severe malaria episodes or death after Community Screening Campaign (CSC) was assessed.</description>
        <time_frame>12 months - period 1</time_frame>
        <population>Safety analyzable carriers set consisted of all infants and children (&gt; 6 months and &lt; 5 years)) from intervention clusters confirmed positive for P. falciparum asexual forms at any CSC or when migrating into the cluster, who in the absence of clinical signs and symptoms received at least one dose of COA566 for the diagnosed asymptomatic infection.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants (Infants and Children (&gt; 6 Months and &lt; 5 Years)) With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC)</title>
          <description>Total number of participants (infants and children (&gt; 6 months and &lt; 5 years)) with hospitalizations, severe malaria episodes or death after Community Screening Campaign (CSC) was assessed.</description>
          <population>Safety analyzable carriers set consisted of all infants and children (&gt; 6 months and &lt; 5 years)) from intervention clusters confirmed positive for P. falciparum asexual forms at any CSC or when migrating into the cluster, who in the absence of clinical signs and symptoms received at least one dose of COA566 for the diagnosed asymptomatic infection.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1023"/>
                <count group_id="O2" value="1040"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe malaria episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Microscopy-confirmed Asymptomatic Carriers From Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Mean number of asymptomatic carriers from Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) was measured by confirmed positive microscopy for P. falciparum asexual forms in participants with absence of clinical signs and symptoms of malaria.
Mean measured in this analysis is the mean percent indicting the mean of percentages of cluster frequencies under the study arm for that particular category.</description>
        <time_frame>12 months - period 1</time_frame>
        <population>The number of units represents the number of clusters that include all randomized participants for which CSC 1, 2 3 and 4 was conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Microscopy-confirmed Asymptomatic Carriers From Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Mean number of asymptomatic carriers from Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) was measured by confirmed positive microscopy for P. falciparum asexual forms in participants with absence of clinical signs and symptoms of malaria.
Mean measured in this analysis is the mean percent indicting the mean of percentages of cluster frequencies under the study arm for that particular category.</description>
          <population>The number of units represents the number of clusters that include all randomized participants for which CSC 1, 2 3 and 4 was conducted, data was available, and census data were obtained as per protocol.</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4859"/>
                <count group_id="O2" value="3542"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC1/ day 1 (n= 2428, 1153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="5.67"/>
                    <measurement group_id="O2" value="47.5" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC2/ day 1 (n= 237, 833)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.62"/>
                    <measurement group_id="O2" value="35.7" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC3/ day 1 (n= 171, 741)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.92"/>
                    <measurement group_id="O2" value="32.2" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4/ day 1 (n= 2023, 815)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="3.92"/>
                    <measurement group_id="O2" value="37.8" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Microscopy-confirmed Gametocyte Carriers at Day 1 of Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Mean number of gametocyte carriers at Day 1 for Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) was measured using gametocyte assessments (prevalence and density) via microscopy.
Mean measured in this analysis is the mean percent indicating the mean of percentages of cluster frequencies under the study arm for that particular category.</description>
        <time_frame>12 months - period 1</time_frame>
        <population>Eligible clusters set consisted of all randomized participants for which CSCs 1, 2, 3 and 4 were conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Microscopy-confirmed Gametocyte Carriers at Day 1 of Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Mean number of gametocyte carriers at Day 1 for Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) was measured using gametocyte assessments (prevalence and density) via microscopy.
Mean measured in this analysis is the mean percent indicating the mean of percentages of cluster frequencies under the study arm for that particular category.</description>
          <population>Eligible clusters set consisted of all randomized participants for which CSCs 1, 2, 3 and 4 were conducted, data was available, and census data were obtained as per protocol.</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="878"/>
                <count group_id="O2" value="633"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC1/Day 1 (n= 543, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.95"/>
                    <measurement group_id="O2" value="10.2" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC2/Day 1 (n= 33, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.38"/>
                    <measurement group_id="O2" value="5.5" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC3/Day 1 (n= 23, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.40"/>
                    <measurement group_id="O2" value="5.8" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4/Day 1 (n= 279, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.34"/>
                    <measurement group_id="O2" value="5.1" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Microscopy and qRT-PCR-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4)</title>
        <description>Number of gametocyte carriers at Community Screening Campaign 4 (CSC4) was measured via microscopy and confirmed using Quantitative Reverse Transcription PCR (qRT-PCR) at day 1 of CSC4.</description>
        <time_frame>Month 12 (CSC4/day 1) - period 1</time_frame>
        <population>Individual subject data from eligible clusters set defined as all randomized participants for which CSC4 was conducted, data was available, and census data was obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Microscopy and qRT-PCR-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4)</title>
          <description>Number of gametocyte carriers at Community Screening Campaign 4 (CSC4) was measured via microscopy and confirmed using Quantitative Reverse Transcription PCR (qRT-PCR) at day 1 of CSC4.</description>
          <population>Individual subject data from eligible clusters set defined as all randomized participants for which CSC4 was conducted, data was available, and census data was obtained as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1023"/>
                <count group_id="O2" value="976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508"/>
                    <measurement group_id="O2" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="514"/>
                    <measurement group_id="O2" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1 (CSC1)/Day 1 to CSC1/Day 28 in Infants and Children (&gt;6 Months and &lt;5 Years) for Asymptomatic Carriers at CSC1</title>
        <description>Change in hemoglobin level (g/dL) from Community Screening Campaign 1 (CSC1)/Day 1 to CSC1/Day 28 in infants and children (&gt;6 Months and &lt;5 Years) for asymptomatic carriers at CSC1 was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
        <time_frame>Day 1 and day 28 - period 1</time_frame>
        <population>Individual subject data from eligible clusters set defined as all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC1 was conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1 (CSC1)/Day 1 to CSC1/Day 28 in Infants and Children (&gt;6 Months and &lt;5 Years) for Asymptomatic Carriers at CSC1</title>
          <description>Change in hemoglobin level (g/dL) from Community Screening Campaign 1 (CSC1)/Day 1 to CSC1/Day 28 in infants and children (&gt;6 Months and &lt;5 Years) for asymptomatic carriers at CSC1 was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
          <population>Individual subject data from eligible clusters set defined as all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC1 was conducted, data was available, and census data were obtained as per protocol.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC1/Day 1 (n=432 ; 179 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.78" spread="1.763"/>
                    <measurement group_id="O2" value="9.67" spread="1.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC1/Day 28 (n=406 ; 174 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.95" spread="1.543"/>
                    <measurement group_id="O2" value="10.17" spread="1.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anemia Status Based on Community Screening Campaign 1 (CSC1)/Day 1 in Infants and Children (&gt;6 Months and &lt;5 Years)</title>
        <description>Anemia status based on Community Screening Campaign 1 (CSC1)/Day 1 in infants and children (&gt;6 months and &lt;5 years) was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
        <time_frame>Day 1 (CSC1/day 1) - period 1</time_frame>
        <population>Individual subject data from eligible clusters set defined as all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC1 was conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Anemia Status Based on Community Screening Campaign 1 (CSC1)/Day 1 in Infants and Children (&gt;6 Months and &lt;5 Years)</title>
          <description>Anemia status based on Community Screening Campaign 1 (CSC1)/Day 1 in infants and children (&gt;6 months and &lt;5 years) was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
          <population>Individual subject data from eligible clusters set defined as all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC1 was conducted, data was available, and census data were obtained as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="819"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC1/Day 1 Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC1/Day 1 Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC1/Day 1 Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC1/Day 1 No symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anemia Status Based on Community Screening Campaign 4 (CSC4)/Day 1 in Infants and Children (&gt;6 Months and &lt;5 Years)</title>
        <description>Anemia status based on Community Screening Campaign 4 (CSC4/Day 1) in infants and children (&gt;6 months and &lt;5 years) was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
        <time_frame>Month 12 (CSC4/day 1) - period 1</time_frame>
        <population>Individual subject data from eligible clusters set defined as all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC4 was conducted, data was available, and census data was obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Anemia Status Based on Community Screening Campaign 4 (CSC4)/Day 1 in Infants and Children (&gt;6 Months and &lt;5 Years)</title>
          <description>Anemia status based on Community Screening Campaign 4 (CSC4/Day 1) in infants and children (&gt;6 months and &lt;5 years) was measured via hemoglobin levels using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant. The anemic status is defined as follows: hemoglobin (Hb) &lt;5 g/dL = severe anemia, Hb 5 to &lt;8 g/dL = moderate anemia, Hb 8 to &lt;11 g/dL = mild anemia, Hb ≥11 g/dL = no anemia).</description>
          <population>Individual subject data from eligible clusters set defined as all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC4 was conducted, data was available, and census data was obtained as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="827"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC4/Day 1 Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4/Day 1 Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4/Day 1 Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4/Day 1 No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448"/>
                    <measurement group_id="O2" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level (g/dL) in Community Screening Campaign 1 (CSC1)/Day 1 and CSC4/Day 1 by Study Arm and Age Group (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Hemoglobin levels at Community Screening Campaign 1 and 4 (CSC1 and CSC4) on day 1 per age group (5-9 years, 10-14 years, and ≥15 years) in the intervention versus the control arm was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant.</description>
        <time_frame>Day 1 (CSC1/day 1) and month 12 (CSC4/day 1) - period 1</time_frame>
        <population>The number of units represents the number of clusters that include all randomized participants (ages 5-9 years, 10-14 years, and ≥15 years) clusters for which CSC1 and CSC4 was conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level (g/dL) in Community Screening Campaign 1 (CSC1)/Day 1 and CSC4/Day 1 by Study Arm and Age Group (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Hemoglobin levels at Community Screening Campaign 1 and 4 (CSC1 and CSC4) on day 1 per age group (5-9 years, 10-14 years, and ≥15 years) in the intervention versus the control arm was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each participant.</description>
          <population>The number of units represents the number of clusters that include all randomized participants (ages 5-9 years, 10-14 years, and ≥15 years) clusters for which CSC1 and CSC4 was conducted, data was available, and census data were obtained as per protocol.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4677"/>
                <count group_id="O2" value="2090"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC1 5- 9 years (n= 899, 431)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.63" spread="0.223"/>
                    <measurement group_id="O2" value="11.59" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4 5 - 9 years (n= 900, 396)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.97" spread="0.224"/>
                    <measurement group_id="O2" value="12.13" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC1 10 - 14 years (n= 873, 380)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.32" spread="0.227"/>
                    <measurement group_id="O2" value="12.71" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4 10 - 14 years (n= 837, 359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.58" spread="0.161"/>
                    <measurement group_id="O2" value="12.72" spread="0.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC1 &gt;= 15 years (n= 2904, 1279)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.13" spread="0.304"/>
                    <measurement group_id="O2" value="13.49" spread="0.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC4 &gt;= 15 years (n= 2760, 1136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.25" spread="0.167"/>
                    <measurement group_id="O2" value="13.42" spread="0.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of COA566-treated Microscopy-confirmed Asymptomatic Carriers at Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3) With Parasitological Cure Rate at Day 7</title>
        <description>Percentage of participants with parasitological cure confirmed via microscopy at day 7 after treatment with COA566. This assessment was done on asymptomatic carriers from Community Screening Campaigns 1, 2 and 3 (CSC1, CSC2 and CSC3) from the intervention group only.</description>
        <time_frame>Day 7 of CSC1, CSC2 and CSC3 - period 1</time_frame>
        <population>Treated asymptomatic carriers from CSC1, CSC2 and CSC3 confirmed by microscopy and treated with study medication. Subjects are counted multiple times if diagnosed and treated more than once during the study. Subjects missing day 7 parasitemia data are excluded. Percentages are based on the number of subjects treated with any formulation.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Not applicable to this outcome measure</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of COA566-treated Microscopy-confirmed Asymptomatic Carriers at Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3) With Parasitological Cure Rate at Day 7</title>
          <description>Percentage of participants with parasitological cure confirmed via microscopy at day 7 after treatment with COA566. This assessment was done on asymptomatic carriers from Community Screening Campaigns 1, 2 and 3 (CSC1, CSC2 and CSC3) from the intervention group only.</description>
          <population>Treated asymptomatic carriers from CSC1, CSC2 and CSC3 confirmed by microscopy and treated with study medication. Subjects are counted multiple times if diagnosed and treated more than once during the study. Subjects missing day 7 parasitemia data are excluded. Percentages are based on the number of subjects treated with any formulation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2450"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC1 (n= 2151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC2 (n=182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC3 (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Microscopy-confirmed Gametocyte Carriers Treated With COA566 for Asymptomatic Carriers</title>
        <description>Percentage of microscopy-confirmed gametocyte asymptomatic carriers treated with COA566 for asymptomatic carriers in Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3).</description>
        <time_frame>Day 1, day 7 and day 28 - period 1</time_frame>
        <population>Treated asymptomatic carriers from CSC1, CSC2 and CSC3 confirmed by microscopy and treated with study medication. Subjects are counted multiple times if diagnosed and treated more than once during the study. Subjects missing day 7 parasitemia data are excluded. Percentages are based on the number of subjects treated with any formulation.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Not applicable to this outcome measure</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Microscopy-confirmed Gametocyte Carriers Treated With COA566 for Asymptomatic Carriers</title>
          <description>Percentage of microscopy-confirmed gametocyte asymptomatic carriers treated with COA566 for asymptomatic carriers in Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3).</description>
          <population>Treated asymptomatic carriers from CSC1, CSC2 and CSC3 confirmed by microscopy and treated with study medication. Subjects are counted multiple times if diagnosed and treated more than once during the study. Subjects missing day 7 parasitemia data are excluded. Percentages are based on the number of subjects treated with any formulation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3970"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSC1 Day 1 (n= 3045)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC 1 Day 7 (n= 3045)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC 1 Day 28 (n= 3045)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC2 Day 1 (n= 850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC2 Day 7 (n= 850)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC3 Day 1 (n= 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSC3 Day 7 (n= 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Community Screening Campaign 1 (CSC1) Infants and Children (&gt;6 Months and &lt;5 Years)- Individual Data</title>
        <description>Individual data of number of asymptomatic carriers with increase in hemoglobin levels by at least 0.5 g/dL from Day 1 to Day 28 from Community Screening Campaign 1 (CSC1) infants and children (&gt;6 months and &lt;5 years). Hemoglobin levels were measured using the HemoCue® rapid test. This test was performed with a drop of blood collected from the fingertip at Day 1 and at Day 28.</description>
        <time_frame>Day 1 to Day 28- period 1</time_frame>
        <population>Individual subject data from eligible clusters set defined as all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC1 was conducted, data was available, and census data was obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Community Screening Campaign 1 (CSC1) Infants and Children (&gt;6 Months and &lt;5 Years)- Individual Data</title>
          <description>Individual data of number of asymptomatic carriers with increase in hemoglobin levels by at least 0.5 g/dL from Day 1 to Day 28 from Community Screening Campaign 1 (CSC1) infants and children (&gt;6 months and &lt;5 years). Hemoglobin levels were measured using the HemoCue® rapid test. This test was performed with a drop of blood collected from the fingertip at Day 1 and at Day 28.</description>
          <population>Individual subject data from eligible clusters set defined as all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC1 was conducted, data was available, and census data was obtained as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="434"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in Infants and Children (&gt;6 Months and &lt;5 Years)- Cluster Data</title>
        <description>Data is presented &quot;per cluster&quot;. Cluster data of number of asymptomatic carriers with increase in hemoglobin levels by at least 0.5 g/dL from Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in infants and children (&gt;6 months and &lt;5 years) was measured by Hemoglobin levels based on microscopy reading.
Mean and Standard Deviation (SD) percent were measured indicating the mean and SD of percentages of cluster frequencies under the study arm for that particular category.</description>
        <time_frame>Day 1 to day 28 - period 1</time_frame>
        <population>The number of units represents the number of clusters that include all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC1 was conducted, data was available, and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in Infants and Children (&gt;6 Months and &lt;5 Years)- Cluster Data</title>
          <description>Data is presented &quot;per cluster&quot;. Cluster data of number of asymptomatic carriers with increase in hemoglobin levels by at least 0.5 g/dL from Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in infants and children (&gt;6 months and &lt;5 years) was measured by Hemoglobin levels based on microscopy reading.
Mean and Standard Deviation (SD) percent were measured indicating the mean and SD of percentages of cluster frequencies under the study arm for that particular category.</description>
          <population>The number of units represents the number of clusters that include all infants and children (&gt;6 months and &lt;5 years) randomized for which CSC1 was conducted, data was available, and census data were obtained as per protocol.</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="434"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" spread="9.17"/>
                    <measurement group_id="O2" value="43.2" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000) in Asymptomatic Carriers at Any Time of Diagnosis (Per Cluster)</title>
        <description>Data is presented &quot;per cluster&quot;. Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) in asymptomatic carriers by study arm from all inhabitants diagnosed at any time for asymptomatic carriers. Number of SMRC5000s is measured by Rapid diagnostic test (RDT) and later confirmed to have a parasite density ≥ 5000/uL by microscopy.</description>
        <time_frame>12 months - period 1</time_frame>
        <population>The number of units represents the number of clusters that include all participants randomized for which data on Symptomatic malaria episode, RDT-confirmed (SMRCs) were collected and census data were obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000) in Asymptomatic Carriers at Any Time of Diagnosis (Per Cluster)</title>
          <description>Data is presented &quot;per cluster&quot;. Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) in asymptomatic carriers by study arm from all inhabitants diagnosed at any time for asymptomatic carriers. Number of SMRC5000s is measured by Rapid diagnostic test (RDT) and later confirmed to have a parasite density ≥ 5000/uL by microscopy.</description>
          <population>The number of units represents the number of clusters that include all participants randomized for which data on Symptomatic malaria episode, RDT-confirmed (SMRCs) were collected and census data were obtained as per protocol.</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2740"/>
                <count group_id="O2" value="1381"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of units</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 SMRC5000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.25" spread="3.531"/>
                    <measurement group_id="O2" value="9.49" spread="3.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 SMRC5000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="1.258"/>
                    <measurement group_id="O2" value="2.78" spread="1.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 SMRC5000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.693"/>
                    <measurement group_id="O2" value="0.97" spread="0.934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 SMRC5000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.664"/>
                    <measurement group_id="O2" value="0.31" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Asymptomatic Carriers With Complicated and Uncomplicated Episodes Combined</title>
        <description>Number of asymptomatic carriers diagnosed with 1 Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000), 2 SMRC5000, 3 SMRC5000 and &gt;3 SMRC5000 (complicated and uncomplicated episodes combined). Number of SMRC5000s is measured by Rapid diagnostic test (RDT) and later confirmed to have a parasite density ≥ 5000/uL by microscopy.</description>
        <time_frame>12 months - period 1</time_frame>
        <population>Individual subject data from eligible clusters set defined as all participants randomized for which data on Symptomatic malaria episode, RDT-confirmed (SMRCs) was collected and census data was obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Asymptomatic Carriers With Complicated and Uncomplicated Episodes Combined</title>
          <description>Number of asymptomatic carriers diagnosed with 1 Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000), 2 SMRC5000, 3 SMRC5000 and &gt;3 SMRC5000 (complicated and uncomplicated episodes combined). Number of SMRC5000s is measured by Rapid diagnostic test (RDT) and later confirmed to have a parasite density ≥ 5000/uL by microscopy.</description>
          <population>Individual subject data from eligible clusters set defined as all participants randomized for which data on Symptomatic malaria episode, RDT-confirmed (SMRCs) was collected and census data was obtained as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2740"/>
                <count group_id="O2" value="1381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 SMRC5000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 SMRC5000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 SMRC5000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 SMRC5000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Subjects With Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL From Week 1 to Week 50</title>
        <description>Cumulative number of asymptomatic carriers having Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) from Week 1 to Week 50, was measured from group of participants diagnosed as asymptomatic carriers at Community Screening Campaign (CSC1)/Day1. Number of participants affected before and after diagnosed with ≥1 symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) (complicated and uncomplicated episodes combined). Number of SMRC5000s was detected by Rapid Diagnostic Test (RDT) using a blood sample from each participant and later confirmed to have a parasite density &gt; or = 5000/uL by microscopy.
Week (1-2) indicates day1 to day14, week (3-4) indicates day 15 to day 28, week (5-6) indicates day 29 to day 42, etc. After first diagnosis of asymptomatic carriers at CSC1/Day1.</description>
        <time_frame>Week 1 to Week 50</time_frame>
        <population>Individual subject data from eligible randomized participants from Community Screening Campaign 1 (CSC1) for which data on Symptomatic malaria episode, RDT-confirmed (SMRCs) was collected and available form analysis and census data was obtained as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Subjects With Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL From Week 1 to Week 50</title>
          <description>Cumulative number of asymptomatic carriers having Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) from Week 1 to Week 50, was measured from group of participants diagnosed as asymptomatic carriers at Community Screening Campaign (CSC1)/Day1. Number of participants affected before and after diagnosed with ≥1 symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000) (complicated and uncomplicated episodes combined). Number of SMRC5000s was detected by Rapid Diagnostic Test (RDT) using a blood sample from each participant and later confirmed to have a parasite density &gt; or = 5000/uL by microscopy.
Week (1-2) indicates day1 to day14, week (3-4) indicates day 15 to day 28, week (5-6) indicates day 29 to day 42, etc. After first diagnosis of asymptomatic carriers at CSC1/Day1.</description>
          <population>Individual subject data from eligible randomized participants from Community Screening Campaign 1 (CSC1) for which data on Symptomatic malaria episode, RDT-confirmed (SMRCs) was collected and available form analysis and census data was obtained as per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2397"/>
                <count group_id="O2" value="1138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week (1-2) n at risk= 2397, 1138</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (3-4) n at risk= 2396, 1133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (5-6) n at risk= 2391, 1129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (7-8) n at risk= 2390, 1124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (9-10) n at risk= 2390, 1123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (11-12) n at risk= 2390, 1121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (13-14) n at risk= 2390, 1103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (15-16) n at risk= 2390, 1102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (17-18) n at risk= 2390, 1102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (19-20) n at risk= 2390, 1102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (21-22) n at risk= 2337, 1083</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (23-24) n at risk= 2311, 1077</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (25-26) n at risk= 2246, 1063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (27-28) n at risk= 2148, 1041</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (29-30) n at risk= 2047, 1020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (31-32) n at risk= 1979, 996</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (33-34) n at risk= 1931, 979</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (35-36) n at risk= 1894, 968</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (37-38) n at risk= 1868, 956</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (39-40) n at risk= 1837, 935</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (41-42) n at risk= 1816, 927</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (43-44) n at risk= 1805, 920</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (45-46) n at risk= 1785, 913</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (47-48) n at risk= 1773, 910</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week (49-50) n at risk= 1758, 904</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety assessed throughout duration of study.</time_frame>
      <desc>Safety assessments consisted of adverse events (AEs) and serious adverse events (SAEs) collection. AEs were collected during a period of 7 days from treatment administration start, for Asymptomatic Carriers and SMRCs only. SAEs were collected in both arms for the entire course of the study; hence the numbers in denominators are not consistent.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention - Period 1</title>
          <description>Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.</description>
        </group>
        <group group_id="E2">
          <title>Control - Period 1</title>
          <description>Participants received COA566 treatment for symptomatic malaria episodes only.</description>
        </group>
        <group group_id="E3">
          <title>Intervention - Period 2 - Follow-up Only</title>
          <description>Participants from the intervention group of period 1 were followed up to assess longer term impact of initial intervention on malaria episodes. No treatment was given to participants during period 2.</description>
        </group>
        <group group_id="E4">
          <title>Control - Period 2- Follow-up Only</title>
          <description>Participants from the control group of period 1 were followed up to assess longer term impact of initial intervention on malaria episodes. No treatment was given to participants during period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>HEART DISEASE CONGENITAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>SICKLE CELL ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>SICKLE CELL ANAEMIA WITH CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVAL PALLOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>EYELID OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA STRANGULATED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>LIP OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>BREAST ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>EXTRAPULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SHIGELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>HEPATIC AMOEBIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>HIV INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>HYDROCELE MALE INFECTED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>INFECTION PARASITIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>MALARIA</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>MENINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>PARASITIC GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>PERITONEAL TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>TYPHOID FEVER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CHEMICAL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>SNAKE BITE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>ABORTION THREATENED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>CERVIX DYSTOCIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF DELIVERY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>FOETAL DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>FOETAL MALPRESENTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>POLYHYDRAMNIOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>STILLBIRTH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>THIRD STAGE POSTPARTUM HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>UTERINE CERVICAL LACERATION DURING LABOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AFFECTIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>PERSONALITY CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>URINARY TRACT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>TESTICULAR TORSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>ASTHMATIC CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4826"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>41 61 324 1111</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

